Combined ¹⁷⁷Lu‐PSMA‐617 PRLT and abiraterone acetate versus ¹⁷⁷Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability

Abstract

In the present study, the combination of ¹⁷⁷ Lu-PSMA-617 PRLT and AA therapy showed significant improvement in mCRPC patients' symptomatic response, PFS, and OS as compared to ¹⁷⁷ Lu-PSMA-617 PRLT monotherapy.